Valutico Alternatives for Pre-Revenue Tech Companies

Valutico is a strong platform aimed at a different reader. Here is how the options split when you are valuing a pre-revenue tech company.

Search for Valutico alternatives for pre-revenue startups and you get software directories. The real shortlist is much shorter than those lists suggest, and most of the tools on them are doing entirely different jobs from each other.

Valutico is built for advisory, audit, banking and private equity teams: its own site describes 850+ advisory, audit, banking, and private equity teams worldwide as its users, and its four named segments are corporate finance and M&A teams, accounting/audit/tax advisory, private equity and investment teams, and banks. Every one of those is a professional intermediary valuing someone else’s company, usually one with a trading history.

For a pre-revenue tech company the alternatives split four ways: dedicated startup-valuation platforms, market-intelligence databases, 409A providers, and DIY spreadsheet templates. Only the first group produces a valuation of your company, from your assumptions. The other three are useful and frequently confused with it. For a fundraising valuation that means Equidam or Eqvista; for benchmarking, Dealroom, PitchBook or Crunchbase; for US option grants, a 409A provider; for learning the mechanics, a spreadsheet.

In the H1 2026 edition of our Valuation Delta, built on 3,000+ pre-seed valuations run on Equidam in the first half of the year, median pre-seed valuation sat at $5.20M against median capital sought of $0.52M (Equidam internal data). That is the centre of gravity for pre-revenue conversations. What a tool changes is whether you can explain where your own number sits inside it, and why.

What are the best alternatives to Valutico for a pre-revenue tech company?

Is Dealroom a valuation tool?

No. Dealroom is a market-intelligence platform, not a valuation tool, and this is the mix-up we see most often. Dealroom describes itself as intelligence for tech ecosystems and the source of record on startups, venture capital and their ecosystems, serving investors, corporates and governments. It is very good at that. It surfaces estimated valuations on companies, which answers “what were companies like mine priced at?” That is a useful question. It is a different question from “what is my company worth on my assumptions, and how do I defend that in a room?”

There is a deeper reason a benchmark can inform a valuation but cannot be one. Gornall and Strebulaev (Journal of Financial Economics, 2020) found that reported unicorn post-money valuations average 48% above fair value, with common shares 56% overvalued, and that 65 of 135 unicorns lose unicorn status once share-class terms such as IPO return guarantees, down-IPO vetoes and seniority are accounted for.

Read the scope carefully. That is measured on unicorns, and the terms doing the damage are late-stage engineering: ratchets, vetoes, stacked seniority. A pre-seed SAFE or a 1x non-participating preferred is nowhere near that, and the same mechanism runs in a much weaker form this early. The principle is what carries down. A headline number is a negotiated price shaped by contract terms, not an estimate of value. At pre-seed the distortion is cruder than share-class engineering. A segment can rest on a handful of rounds, and every one of those prices was set by two people in a room. Aggregated across enough rounds the data is still worth having, which is why we use it ourselves and publish where it comes from. What it cannot do is stand in for your own number. Anchor to it and you import someone else’s circumstances along with their price.

The everyday version of the same problem is the revenue multiple. Benchmark’s Bill Gurley called the price/revenue multiple “the crudest valuation tool of them all” back in 2011, and we have been making a version of that argument ever since. Our own word for it is procyclical: multiples rise and fall with market mood rather than with the business, and they are easy to game. Suppose the going rate is 16x ARR. Book another $500k by discounting hard and buying customers who churn out again next year, and the headline moves by $8M while the economics underneath get worse. The multiple did all of that work by itself.

Comparables still have a role. Run them after you have a valuation, as a sanity check on the implied multiples it produces.

Is a 409A the same as a fundraising valuation?

No. A 409A is a US tax-compliance exercise that sets the fair market value of common stock so option strike prices sit inside safe harbour. It is backward-looking by design, deliberately conservative, and produced for the IRS. The valuation you take into an investor conversation is forward-looking and built on your own projections; a 409A is a different document for a different reader.

Whether it applies to you is a narrower question than where you are incorporated. Section 409A covers deferred compensation received by a US taxpayer, so on the face of the statute what matters is generally who holds the award and files a US return, not the flag on the certificate. Grant options to someone who files a US return and you typically have a 409A question to answer, wherever the company itself sits. A Delaware subsidiary on its own does not settle it in either direction. That is how we read the text, not advice: if any of your option-holders are US taxpayers, talk to a tax adviser rather than to a valuation tool. Cap-table platforms bundle it with equity management, which is convenient, and which makes it easy to mistake for a fundraising number.

What about DIY templates?

They are free and transparent, and building one teaches you more about your business than any tool will. Where they fall down is inputs. A DCF needs a risk-free rate, a country market risk premium, an industry-and-stage-adjusted beta, survival rates and current multiples. Sourcing those yourself, keeping them current, and being able to say where each came from when an investor asks is where the real work sits. That is why we publish every input and its source: 30,000+ listed comparables updated weekly, US BLS and Eurostat survival data, Damodaran/NYU Stern for betas and risk premiums, Crunchbase for recent angel and pre-seed rounds.

Why professional toolkits struggle before revenue

We have valued 160,000+ companies across 90+ countries and 600+ industries (Equidam internal data), and the pre-revenue ones fail a professional toolkit in the same three places every time.

The first is the input the toolkit is built to consume: a trading history. There is no previous year to average, this year is a stub, and the book value is a laptop and some legal fees. You can see the assumption written into the machinery. Valutico’s own breakdown of trading and transaction multiples works each multiple across previous year, current year and next year, with adjustments to strip out extraordinary items. A pre-revenue company has no previous year, a token current year, and only a projection for next year. Nothing is wrong with the design. It was built for companies that have the numbers. Aswath Damodaran wrote up the same conclusion in Valuing Young, Start-up and Growth Companies (NYU Stern, 2009): “Since most of them report losses early in the life cycle, multiples such as price earnings ratios and EBITDA multiples cannot be computed. Since the firm has been in operation only a short period, the book value is likely to be a very small number… Even revenues can be problematic, since they can be non-existent for idea companies.”

The second is comparables, the usual escape hatch, and it does not rescue anything. Whatever the industry, the closest peers to a pre-revenue company are almost always private and unpriced, and the listed ones left over are a different business at a different point in its life. Damodaran again: “With young companies, the comparison would logically be to other young companies in the same business but these companies are usually not publicly traded and have no market prices… We could look at the multiples at which publicly traded firms in the same sector trade at, but these firms are likely to have very different risk, cash flow and growth characteristics.” The pool is thinning too: Ewens and Farre-Mensa (NBER, 2021) document a sharp decline in the number of firms going public, with those that do arriving older and better funded.

The third is risk, and it is the one that catches founders out. Beta and standard deviation are computed from a share price, and a pre-revenue company does not have one. That is why we source an adjusted beta by industry, stage, size and profitability instead of measuring it, and why every projected year gets discounted by a survival rate. Damodaran reached both points first: market-based risk proxies “cannot be computed for young companies that are privately held”, and “the fact that most young companies do not survive has to be considered somewhere in the valuation.”

To be fair to Valutico: its valuation page says the platform can support early-stage, SME, mid-market, and investment cases in one workflow, and the method coverage behind that is broad. The same page advertises 30+ valuation methods in one structured workflow, among them DCF, EBITDA multiples, revenue multiples and book value, every one of which needs a trading history to run. Start-up-specific material sits alongside that list. Valutico added a Venture Capital Method for valuing start-ups to the platform, and its guide to start-up valuation methods points pre-seed and seed companies at Berkus and Scorecard, reserving the First Chicago Method for later stages with more financial predictability. What differs is what the workflow is organised around. Valutico sells to advisory, audit, banking and private equity teams, and early-stage is one of the cases it handles inside that. If you want the direct feature-by-feature version of that argument, we have written it up separately in Equidam vs Valutico. Pricing is not published; the site routes to a demo.

What a pre-revenue method has to do

Four requirements. They are also the criteria to judge any tool on. We have written at more length about what to expect from a startup valuation platform; this is the pre-revenue-specific short list.

Be forward-looking. Bill Gurley’s point is that founders read a valuation as an award for past behaviour. In his words: “It’s not. It’s a hurdle for future behavior.” It is a statement about future potential and the risk of reaching it, which also means the underlying financial model can be short. Three years is enough for most pre-revenue companies. You stretch further only when no product launch sits inside three years, as with some hard tech.

Structure the qualitative evidence. Team, market, product differentiation, competitive barriers, early validation: before revenue these are the evidence. The Scorecard and Checklist methods turn them into something comparable and reviewable, with each judgement recorded against a defined criterion a reader can question.

Adjust the quantitative side for startup reality. Three adjustments carry most of the load. Discount each projected year’s cash flows by a survival rate, so the model prices in the chance the company never gets there. Apply an illiquidity discount, which reflects how hard private shares are to sell. And build the cost of equity from CAPM, the standard formula for turning market risk into a discount rate, using a beta (a measure of how volatile a company is relative to the overall market) adjusted for industry, stage, size and profitability. Those three are what make a DCF usable before revenue.

Then triangulate, rather than betting on one method. Every method carries its own bias, and each one answers a different part of the question: the DCF sets the goalposts, the VC method shows the size of the prize, and the qualitative methods show how likely you are to score. Equidam’s approach uses five: two qualitative (Scorecard, Checklist) and three quantitative (DCF with Long-Term Growth, DCF with Multiples, Venture Capital method), combined into a weighted average that shifts with stage. Qualitative methods carry most weight at idea and pre-seed; quantitative methods take over as a financial history appears.

There is an obvious objection to that last point. The same Damodaran paper is sharply critical of the venture capital method as commonly practised, listing game-playing on projected earnings and premature exit-multiple cut-offs among its problems. We think that critique lands on the VC method used alone as the entire valuation. As one weighted input beside four others, it contributes the thing it is good at, the investor’s required-return perspective, without being allowed to set the answer by itself.

Where Equidam fits, and where it doesn’t

The table leaves out two things. The first is what comes out at the end. The report shows the calculation behind each of the five methods, because the conversation with an investor is about the assumptions. The inputs feeding those methods are named and dated across 90+ countries and 600+ industries, with 160,000+ companies valued to date and 94% positive investor feedback (Equidam internal data). You can run the full engine on the free tier without a card; paid tiers start from €338.50 excl. VAT.

The second is method weights, which is what founders ask about when they compare us to Eqvista. Eqvista covers Berkus, Scorecard, Risk Factor, VC and DCF with custom weighting tools that let users adjust each method’s impact. Equidam starts from a default weighting schedule set by development stage and published in advance in the sample report, so the reason a weight looks the way it does is something you can point to, and any change from the defaults is visible as a change.

And the limits. If you are a licensed advisor valuing SMEs and mid-market deals for clients, Valutico is the better-fitting product. If you need a US 409A safe-harbour opinion, get one from a 409A provider. If you want ecosystem market intelligence, Dealroom does that better than any valuation engine will.

Where to start

Pick the tool by the job. If you are raising, the work starts before the software: write down the assumptions you would stand behind under questioning, in roughly the order an investor will ask about them.

1. The market. How big it is, how you sized it, and which slice you are actually addressing.
2. The revenue path. Three years of it, and what has to be true for each year to happen.
3. The cost structure. The hires, the burn, and the point at which the plan turns cash-positive.
4. The capital. How much you need, the milestone it buys, and what the milestone proves.
5. The exit picture. Who buys companies like yours, and at what kind of multiple.

Those five are what the conversation will be about, and they are the inputs any of these tools will ask you for anyway. Then run the numbers somewhere that shows its working. Equidam’s free tier gives you an on-screen range with the breakdown of each method behind it; the downloadable report sits on the paid tiers. For the full methodology, the startup valuation guide covers it end to end.